Cardiology

Evaluating Ultra-Long-Term Survival and Myocardial Infarction Rates Following Initial Revascularization in Stable CAD

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  JAMA https://doi.org/10.1001/jama.2026.23488
Dr. Neel M. Butala et al.

Points

  • University of Colorado Anschutz researchers conducted an extended observational follow up of nine hundred fifty nine veteran participants from the original randomized COURAGE trial for stable coronary artery disease.
  • Using linked health records over a median follow up of fifteen years extending to twenty five years investigators evaluated the long term composite risk of death or myocardial infarction.
  • Statistical analysis established that the estimated twenty five year cumulative incidence of death or myocardial infarction was ninety three point three percent with initial percutaneous coronary intervention.
  • Patients initially assigned to optimal medical therapy alone experienced an estimated twenty five year cumulative incidence of death or myocardial infarction of ninety one percent showing no significant difference.
  • Authors concluded that while coronary stenting effectively relieves anginal symptoms adding routine initial revascularization to medical therapy does not lower long term mortality or heart attack risk.

Summary

This post hoc observational follow-up study evaluated the 25-year cumulative incidence of death or myocardial infarction (MI) comparing an initial strategy of percutaneous coronary intervention (PCI) plus optimal medical therapy (OMT) against OMT alone in patients with stable coronary artery disease (CAD). Published in JAMA and presented at the 2026 American Heart Association Scientific Sessions by researchers led by Dr. Neel Butala of the University of Colorado Anschutz School of Medicine, the investigation extended observations from the original COURAGE trial. Given that earlier trials—including COURAGE at 4.6 and 11.9 years and ISCHEMIA at 3.2 years—showed no early mortality advantage but raised questions regarding potential late divergence in spontaneous MI rates, the study sought to clarify ultra-long-term ischemic and survival outcomes.

The analysis tracked 959 veteran participants from the original randomized COURAGE cohort using linked administrative health records over a median follow-up of 15 years, extending up to 25 years. Investigators found no statistically significant difference in the composite primary endpoint of death or MI between treatment strategies. At 25 years, the estimated cumulative incidence of death or MI was 93.3% among patients initially assigned to PCI plus OMT, compared with 91.0% among those assigned to OMT alone.

The authors conclude that adding initial routine PCI to optimal medical therapy does not reduce the long-term combined risk of mortality or myocardial infarction over 25 years in patients with stable CAD. While coronary revascularization remains vital for symptom relief and acute coronary syndromes, these extended findings reinforce optimal medical therapy as the foundational management strategy for stable disease, supporting informed shared decision-making between clinicians and patients.

Link to the article: https://jamanetwork.com/journals/jama/article-abstract/2856313#google_vignette 

References

Butala, N. M., Murali, N., Rahman, N., Cave, S., Ayandeh, S., Plomondon, M. E., Cunningham, J. W., Weintraub, W. S., Yeh, R. W., Waldo, S. W., & Boden, W. E. (2026). Percutaneous coronary intervention and long-term outcomes in stable coronary artery disease: Extended follow-up of the courage randomized trial. JAMA. https://doi.org/10.1001/jama.2026.23488

About the author

Hippocrates Briefs Team

Leave a Comment